scholarly journals Association of Polymorphisms of the Receptor for Advanced Glycation End Products Gene and Susceptibility to Sporadic Abdominal Aortic Aneurysm

2015 ◽  
Vol 2015 ◽  
pp. 1-10 ◽  
Author(s):  
Ye Yao ◽  
Junli Zhuang ◽  
You Li ◽  
Bao Jing ◽  
Hali Li ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Gene Polymorphisms ◽  
Smoking Status ◽  
Aortic Aneurysms ◽  
Advanced Glycation ◽  
Soluble Rage ◽  
Abdominal Aortic ◽  
Significant Difference ◽  
Glycation End Products ◽  
End Products

Accumulating evidence has suggested that receptor for advanced glycation end products (RAGE) is involved in the development and progression of human abdominal aortic aneurysms (AAAs). However, the association betweenRAGEgene polymorphisms and AAA has not yet been determined. The present study was aimed at analyzing the potential association between theRAGEgene polymorphisms and AAAs. A cohort of 381 patients and 436 age-matched healthy controls were genotyped to detect the threeRAGEpolymorphisms (−374 T/A, −429 T/C, and G82S) using SNaPshot. Our study demonstrated a significant difference in the genotype and allele frequencies of theRAGEG82S polymorphism between the AAA patients and the controls. Further stratification by gender and smoking status revealed that the presence of theRAGE82S allele confers a higher risk for developing AAA in men and smokers. Moreover, AAA patients with the variant 82S allele ofRAGEpresented with reduced serum soluble RAGE (sRAGE) production, and this decrease was more significant in men and smokers with AAA. Our study provides preliminary evidence that the 82S allele ofRAGEis a risk factor for AAA. This new piece of knowledge regarding RAGE may be clinically important for the prevention and therapy of AAAs.

Soluble RAGE Sequesters Advanced Glycation End Products following an Overnight Fast in T1DM Patients

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 275-LB
Author(s):  
EDWIN R. MIRANDA ◽  
JR. KELLY N. FULLER ◽  
RYAN PERKINS ◽  
PAUL J. BEISSWENGER ◽  
SARAH S. FARABI ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Soluble Rage ◽  
Glycation End Products ◽  
End Products

Receptor for advanced glycation end products (RAGE) and glyoxalase I gene polymorphisms in pathological pregnancy

2012 ◽  
Vol 45 (16-17) ◽  
pp. 1409-1414 ◽  
Author(s):  
Anna Germanová ◽  
Alexandra Muravská ◽  
Marie Jáchymová ◽  
Zdeněk Hájek ◽  
Michal Koucký ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Gene Polymorphisms ◽  
Glyoxalase I ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Pathological Pregnancy ◽  
I Gene

scholarly journals Skin accumulation of advanced glycation end products is increased in patients with an abdominal aortic aneurysm

2017 ◽  
Vol 66 (6) ◽  
pp. 1696-1703.e1 ◽  
Author(s):  
Jeltje Boersema ◽  
Lisanne C. de Vos ◽  
Thera P. Links ◽  
Douwe J. Mulder ◽  
Andries J. Smit ◽  
...  
Keyword(s):  
Abdominal Aortic Aneurysm ◽  
Aortic Aneurysm ◽  
Advanced Glycation End Products ◽  
Advanced Glycation ◽  
Abdominal Aortic ◽  
Skin Accumulation ◽  
Glycation End Products ◽  
End Products

Distribution of the Receptor for Advanced Glycation End Products Gene Polymorphisms in Patients With Chronic Periodontitis: A Preliminary Study

2001 ◽  
Vol 72 (12) ◽  
pp. 1742-1746 ◽  
Author(s):  
Lydie Izakovičová Hollá ◽  
Kateřina Kaňková ◽  
Antonín Fassmann ◽  
Dana Bučková ◽  
Tomáš Halabala ◽  
...  
Keyword(s):  
Advanced Glycation End Products ◽  
Chronic Periodontitis ◽  
Gene Polymorphisms ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Preliminary Study

scholarly journals Proteolytic release of the receptor for advanced glycation end products from in vitro and in situ alveolar epithelial cells

2011 ◽  
Vol 300 (4) ◽  
pp. L516-L525 ◽  
Author(s):  
Naoko Yamakawa ◽  
Tokujiro Uchida ◽  
Michael A. Matthay ◽  
Koshi Makita
Keyword(s):  
Epithelial Cells ◽  
Advanced Glycation End Products ◽  
Alveolar Epithelial Cells ◽  
Advanced Glycation ◽  
Alveolar Epithelial ◽  
Lps Challenge ◽  
Soluble Rage ◽  
Glycation End Products ◽  
End Products

Although the receptor for advanced glycation end products (RAGE) has been used as a biological marker of alveolar epithelial cell injury in clinical studies, the mechanism for release of soluble RAGE from lung epithelial cells has not been well studied. Therefore, these studies were designed to determine the mechanism for release of soluble RAGE after lipopolysaccharide (LPS) challenge. For these purposes, alveolar epithelial cells from rat lungs were cultured on Transwell inserts, and LPS was added to the apical side (500 μg/ml) for 16 h on day 7. On day 7, RAGE was expressed predominantly in surfactant protein D-negative cells, and LPS challenge induced release of RAGE into the medium. This response was partially blocked by matrix metalloproteinase (MMP) inhibitors. Transcripts of MMP-3 and MMP-13 were upregulated by LPS, whereas RAGE transcripts did not change. Proteolysis by MMP-3 and MMP-13 resulted in soluble RAGE expression in the bronchoalveolar lavage fluid in the in situ rat lung, and this reaction was inhibited by MMP inhibitors. In human studies, both MMP-3 and -13 antigen levels were significantly correlated with the level of RAGE in pulmonary edema fluid samples. These results support the conclusion that release of RAGE is primarily mediated by proteolytic damage in alveolar epithelial cells in the lung, caused by proteases in acute inflammatory conditions in the distal air spaces.

Receptor for advanced glycation end-products (RAGE) - soluble form (sRAGE) and gene polymorphisms in patients with breast cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 21113-21113
Author(s):  
P. Tesarova ◽  
M. Kalousova ◽  
M. Jachymova ◽  
O. Mestek ◽  
L. Petruzelka ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Estrogen Receptors ◽  
Advanced Glycation End Products ◽  
Gene Polymorphisms ◽  
Soluble Form ◽  
Healthy Controls ◽  
Serum Concentrations ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products

21113 Background: Receptor for advanced glycation end products (RAGE) may be involved in the pathogenesis of the cancer progression and metastasis. Pathological effects mediated via RAGE are physiologically inhibited by soluble RAGE (sRAGE), so the higher sRAGE levels may confer the patients with cancer with better outcome.. Our aim was to study sRAGE and RAGE gene polymorphisms in patients with breast cancer. Methods: We studied sRAGE and RAGE polymorphisms in 120 patients with breast cancer (subdivided based on the clinical stage, histologic grading, expression of hormonal and C-erb B2 receptors) and in 92 healthy controls. Results: Despite higher serum concentrations of AGEs, serum concentrations of sRAGE were lower in patients with breast cancer compared to healthy controls (1581 ± 777 vs. 1803 ± 632 ng/ml, p < 0.05). Serum levels of sRAGE were higher in patients with advanced breast cancer (stage III), lower grade and positive estrogen receptors and intermediate positivity of C-erb B2 (Her-neu) receptors and were also influenced genetically (G82S and 2184 AG polymorphisms of the RAGE gene). Conclusions: Decreased sRAGE levels in patients with breast cancer may contribute to the progression of the disease. Patients with better outcome (with low grade and positive estrogen receptors) have higher sRAGE levels. Progression of the disease, may, however, increase sRAGE levels, possibly as a compensatory mechanism to counteract further progression. No significant financial relationships to disclose.

scholarly journals Association of the Receptor for Advanced Glycation End Products Gene Polymorphisms and Circulating RAGE Levels with Diabetic Retinopathy in the Chinese Population

2013 ◽  
Vol 2013 ◽  
pp. 1-8 ◽  
Author(s):  
Li Yang ◽  
Qunhong Wu ◽  
Yuan Li ◽  
Xiaohong Fan ◽  
Yanhua Hao ◽  
...  
Keyword(s):  
Diabetic Retinopathy ◽  
Advanced Glycation End Products ◽  
Chinese Population ◽  
Genetic Interaction ◽  
Interaction Model ◽  
Serum Levels ◽  
Advanced Glycation ◽  
Soluble Rage ◽  
Glycation End Products ◽  
End Products

Objectives. This study investigated the association between polymorphisms in the receptor for advanced glycation end products (RAGE) gene and the susceptibility to diabetic retinopathy (DR) in a Chinese population and identified a correlation between serum-soluble RAGE (sRAGE) levels and DR risk.Materials and Methods. We enrolled 1040 patients with type 2 diabetes mellitus: 372 patients with DR and 668 without retinopathy (NDR). All polymorphisms were genotyped by time-of-flight mass spectrometry. Serum levels of sRAGE were assayed by enzyme-linked immunosorbent assays. The interaction of SNPs was analyzed by multifactor dimensionality reduction (MDR).Results. The frequency of the SS genotype for the G82S polymorphism was 12.4% in the DR group and 6.6% in the NDR group; this difference was significant. G82S was associated with sRAGE levels. Specifically, after adjustments for age, sex, duration, and glucose metabolism, serum sRAGE levels were significantly higher in DR subjects with the S/S genotype than in NDR subjects in general. In the DR group, subjects with the G/S genotype had lower sRAGE levels than subjects with the G/G or S/S genotype (P<0.01). The best multilocus genetic interaction model was assessed using the MDR method; 2184A/G, 1704G/T, G82S, and −429T/C were identified.Conclusions. The findings suggest that the G82S polymorphism in theRAGEgene is associated with DR risk, and G82S was associated with circulating levels of sRAGE. The mechanism by which G82S polymorphism modulates the sRAGE levels remains to be elucidated.

ID: 83: PRODUCTION OF SOLUBLE RECEPTOR FOR ADVANCED GLYCATION END-PRODUCTS FOLLOWING ACUTE AEROBIC EXERCISE IS GENDER SPECIFIC

2016 ◽  
Vol 64 (4) ◽  
pp. 928.2-929
Author(s):  
ER Miranda ◽  
JT Mey ◽  
BK Blackburn ◽  
JM Haus ◽  
SS Farabi ◽  
...  
Keyword(s):  
Aerobic Exercise ◽  
Advanced Glycation End Products ◽  
Acute Exercise ◽  
Primary Objective ◽  
Advanced Glycation ◽  
Insulin Resistant ◽  
Soluble Rage ◽  
Downstream Effectors ◽  
Glycation End Products ◽  
End Products

The Receptor for Advanced Glycation End Products (RAGE) is a transmembrane receptor that initiates a self-propagating inflammatory cascade and has been implicated in the onset of complications involved with aging, diabetes and neuroinflammation. Soluble RAGE (sRAGE) inhibits this inflammatory signaling by competitively binding to RAGE ligands without stimulating downstream effectors. Evidence from our lab demonstrates chronic aerobic exercise increases the cleaved isoform of sRAGE (sRAGEc). However, the effects of acute aerobic exercise on sRAGEc production have not been comprehensively examined. Furthermore, recent data suggests that estrogen may play a role in exacerbating RAGE signaling and perturbing sRAGE production in diabetic women. Therefore, the primary objective of this study was to investigate changes in plasma sRAGE with acute aerobic exercise in both lean healthy (LH) and obese insulin resistant (OB-IR) individuals. A secondary objective of the study was to compare exercise responses between men and women. 8 LH participants (4 M, 4 F) and 14 OB-IR participants (4 M, 10 F) were recruited for the study. VO2max was determined via treadmill test and participants returned to the lab on a separate day following an overnight fast and exercised at 65% VO2max for 30 minutes. Blood samples were collected before and following exercise after participants rested in seated position for 30 minutes. Quantification of plasma sRAGE and endogeonous secretory RAGE were determined via ELISA and sRAGEc was calculated by subtraction. Between-group comparisons were made via independent T Test and the effect of gender was analyzed via two-way ANOVA. At baseline the OB-IR group was older (41±3 y vs. 26±1 y, p<.001), more obese (BMI 35.1±0.9 vs. 22.2±0.9 kg . m−2, p<.001) and less aerobically fit (VO2max 27.8±1.8 vs. 50.2±2.9 mL/kg−1. min−1, p<.001) compared the LH group. There was no main effect of group (OB-IR vs. LHC) on change in sRAGE or sRAGEc in response to exercise (ΔsRAGE 20.3±53.2 vs. 13.8±34.4 pg/mL, p=.93), (ΔsRAGEc 28.7±47.1 vs. 14.4±34.8 pg/mL, p=.33). However there was an effect of gender on the response to acute exercise. Males in both groups saw a significantly greater increase in plasma sRAGE (131.49±46.46 vs. −46.94±39.23 pg/mL, p<.05) and plasma sRAGEc (127.73±47.04 vs. −36.08±34.13 pg/mL, p<.05) compared to females. This study is the first to show that young healthy women and obese/insulin resistant women have an impaired ability to increase sRAGE plasma levels with acute aerobic exercise. Recent data has suggested that estrogen can exacerbate RAGE signaling as well as inhibit sRAGE production although the precise mechanism for this interaction is unclear and warrants further investigation.

Sign in / Sign up

Export Citation Format

Share Document